Solid Biosciences (SLDB) Net Income towards Common Stockholders (2017 - 2024)
Historic Net Income towards Common Stockholders for Solid Biosciences (SLDB) over the last 7 years, with Q4 2024 value amounting to -$38.0 million.
- Solid Biosciences' Net Income towards Common Stockholders fell 8463.55% to -$38.0 million in Q4 2024 from the same period last year, while for Dec 2024 it was -$120.6 million, marking a year-over-year decrease of 2418.8%. This contributed to the annual value of -$120.6 million for FY2024, which is 2418.8% down from last year.
- According to the latest figures from Q4 2024, Solid Biosciences' Net Income towards Common Stockholders is -$38.0 million, which was down 8463.55% from -$32.9 million recorded in Q3 2024.
- In the past 5 years, Solid Biosciences' Net Income towards Common Stockholders registered a high of -$19.0 million during Q2 2020, and its lowest value of -$38.0 million during Q4 2024.
- In the last 4 years, Solid Biosciences' Net Income towards Common Stockholders had a median value of -$24.9 million in 2023 and averaged -$25.6 million.
- In the last 5 years, Solid Biosciences' Net Income towards Common Stockholders skyrocketed by 3761.81% in 2023 and then crashed by 8463.55% in 2024.
- Solid Biosciences' Net Income towards Common Stockholders (Quarter) stood at -$21.4 million in 2020, then tumbled by 54.62% to -$33.0 million in 2022, then skyrocketed by 37.62% to -$20.6 million in 2023, then plummeted by 84.64% to -$38.0 million in 2024.
- Its Net Income towards Common Stockholders stands at -$38.0 million for Q4 2024, versus -$32.9 million for Q3 2024 and -$25.3 million for Q2 2024.